These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 15454681)

  • 21. Evaluation of EPA's Tier 1 Endocrine Screening Battery and recommendations for improving the interpretation of screening results.
    Borgert CJ; Mihaich EM; Quill TF; Marty MS; Levine SL; Becker RA
    Regul Toxicol Pharmacol; 2011 Apr; 59(3):397-411. PubMed ID: 21251942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of a Tier I screening battery for detecting endocrine-active compounds (EACs).
    Cook JC; Kaplan MA; Davis LG; O'Connor JC
    Regul Toxicol Pharmacol; 1997 Aug; 26(1 Pt 1):60-8. PubMed ID: 9339481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of in vivo assays for endocrine disruption.
    Clode SA
    Best Pract Res Clin Endocrinol Metab; 2006 Mar; 20(1):35-43. PubMed ID: 16522518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Scientific and Regulatory Policy Committee (SRPC) Points to Consider: Histopathology Evaluation of the Pubertal Development and Thyroid Function Assay (OPPTS 890.1450, OPPTS 890.1500) in Rats to Screen for Endocrine Disruptors.
    Keane KA; Parker GA; Regan KS; Picut C; Dixon D; Creasy D; Giri D; Hukkanen RR
    Toxicol Pathol; 2015 Dec; 43(8):1047-63. PubMed ID: 25948506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of the environmental antiandrogen p,p-DDE in CD and long-evans rats using a tier I screening battery and a Hershberger assay.
    O'Connor JC; Frame SR; Davis LG; Cook JC
    Toxicol Sci; 1999 Sep; 51(1):44-53. PubMed ID: 10496676
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Application of an integrated testing strategy to the U.S. EPA endocrine disruptor screening program.
    Willett CE; Bishop PL; Sullivan KM
    Toxicol Sci; 2011 Sep; 123(1):15-25. PubMed ID: 21642633
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selecting the appropriate rodent diet for endocrine disruptor research and testing studies.
    Thigpen JE; Setchell KD; Saunders HE; Haseman JK; Grant MG; Forsythe DB
    ILAR J; 2004; 45(4):401-16. PubMed ID: 15454679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endocrine disrupters--testing strategies to assess human hazard.
    Baker VA
    Toxicol In Vitro; 2001; 15(4-5):413-9. PubMed ID: 11566572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An ongoing validation of a Tier I screening battery for detecting endocrine-active compounds (EACs).
    O'Connor JC; Cook JC; Slone TW; Makovec GT; Frame SR; Davis LG
    Toxicol Sci; 1998 Nov; 46(1):45-60. PubMed ID: 9928668
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toxicity testing and endocrine disrupting chemicals.
    Vandenberg LN
    Adv Pharmacol; 2021; 92():35-71. PubMed ID: 34452691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The immature mouse is a suitable model for detection of estrogenicity in the uterotropic bioassay.
    Padilla-Banks E; Jefferson WN; Newbold RR
    Environ Health Perspect; 2001 Aug; 109(8):821-6. PubMed ID: 11564618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Using in vitro high throughput screening assays to identify potential endocrine-disrupting chemicals.
    Rotroff DM; Dix DJ; Houck KA; Knudsen TB; Martin MT; McLaurin KW; Reif DM; Crofton KM; Singh AV; Xia M; Huang R; Judson RS
    Environ Health Perspect; 2013 Jan; 121(1):7-14. PubMed ID: 23052129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lessons learned, challenges, and opportunities: the U.S. Endocrine Disruptor Screening Program.
    Juberg DR; Borghoff SJ; Becker RA; Casey W; Hartung T; Holsapple MP; Marty MS; Mihaich EM; Van Der Kraak G; Wade MG; Willett CE; Andersen ME; Borgert CJ; Coady KK; Dourson ML; Fowle JR; Gray LE; Lamb JC; Ortego LS; Schug TT; Toole CM; Zorrilla LM; Kroner OL; Patterson J; Rinckel LA; Jones BR
    ALTEX; 2014; 31(1):63-78. PubMed ID: 24114257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FIFRA Subdivision F testing Guidelines: are these tests adequate to detect potential hormonal activity for crop protection chemicals? Federal Insecticide, Fungicide, and Rodenticide Act.
    Stevens JT; Tobia A; Lamb JC; Tellone C; O'Neal F
    J Toxicol Environ Health; 1997 Apr; 50(5):415-31. PubMed ID: 9140462
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of EPA's endocrine screening battery and recommendations for further review.
    Schapaugh AW; McFadden LG; Zorrilla LM; Geter DR; Stuchal LD; Sunger N; Borgert CJ
    Regul Toxicol Pharmacol; 2015 Aug; 72(3):552-61. PubMed ID: 26044367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Key learnings from the Endocrine Disruptor Screening Program (EDSP) Tier 1 rodent uterotrophic and Hershberger assays.
    Marty MS; O'Connor JC
    Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):63-79. PubMed ID: 24515841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Laboratory animal science issues in the design and conduct of studies with endocrine-active compounds.
    Everitt JI; Foster PM
    ILAR J; 2004; 45(4):417-24. PubMed ID: 15454680
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sensitivity of a Tier I screening battery compared to an in utero exposure for detecting the estrogen receptor agonist 17 beta-estradiol.
    O'Connor JC; Frame SR; Biegel LB; Cook JC; Davis LG
    Toxicol Sci; 1998 Aug; 44(2):169-84. PubMed ID: 9742655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A predictive data-driven framework for endocrine prioritization: a triazole fungicide case study.
    Paul Friedman K; Papineni S; Marty MS; Yi KD; Goetz AK; Rasoulpour RJ; Kwiatkowski P; Wolf DC; Blacker AM; Peffer RC
    Crit Rev Toxicol; 2016 Oct; 46(9):785-833. PubMed ID: 27347635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypothesis-driven weight of evidence evaluation indicates styrene lacks endocrine disruption potential.
    Borgert CJ
    Crit Rev Toxicol; 2023 Feb; 53(2):53-68. PubMed ID: 37216681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.